All Stories

  1. Evaluation of the analytic performance and macroprolactin sensitivity of a new prolactin immunoassay

    Article • Annales d Endocrinologie, April 2025, Elsevier

    Professor Gerald Raverot

  2. Aggressive Pituitary Tumors and Pituitary Carcinomas: definition, management and overview for clinical practice

    Article • Neuro-Oncology Advances, January 2025, Oxford University Press (OUP)

    Professor Gerald Raverot

  3. A promising new direct immunoassay for urinary free cortisol determination

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), December 2024, De Gruyter

    Professor Gerald Raverot

  4. Evidence for somatic mutation screening on aggressive prolactinomas

    Article • Nature Reviews Endocrinology, June 2024, Springer Science + Business Media

    Professor Gerald Raverot

  5. Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2024, Endocrine Society

    Professor Gerald Raverot

  6. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial

    Article • European Journal of Endocrinology, March 2024, Oxford University Press (OUP)

    Professor Gerald Raverot

  7. Letter to the Editor From Salle et al.: “A Prospective Multicenter Observational Study of Surgical Versus non-surgical Management for Pituitary Apoplexy”

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2024, Endocrine Society

    Professor Gerald Raverot

  8. Carney complex predisposes to breast cancer: prospective study of 50 women

    Article • European Journal of Endocrinology, January 2024, Oxford University Press (OUP)

    Professor Gerald Raverot

  9. Pasireotide: potential treatment option for McCune–Albright-associated acromegaly

    Article • European Journal of Endocrinology, December 2023, Oxford University Press (OUP)

    Professor Gerald Raverot

  10. Evidence of Persistent Mild Hypercortisolism in Patients Medically Treated for Cushing Disease: the Haircush Study

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2023, Endocrine Society

    Professor Gerald Raverot

  11. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal

    Article • Endocrine Related Cancer, April 2023, Bioscientifica

    Professor Gerald Raverot

  12. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question

    Article • European Journal of Endocrinology, March 2023, Oxford University Press (OUP)

    Professor Gerald Raverot

  13. Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature

    Article • Brain Sciences, March 2023, MDPI AG

    Professor Gerald Raverot

  14. Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review

    Article • Endocrine Related Cancer, February 2023, Bioscientifica

    Professor Gerald Raverot

  15. Inhibition of activin signalling reduces the growth of LβT2 gonadotroph pituitary tumours in mouse

    Article • Endocrine Related Cancer, January 2023, Bioscientifica

    Professor Gerald Raverot

  16. IGSF1 mutations are the most frequent genetic aetiology of thyrotropin deficiency

    Article • European Journal of Endocrinology, November 2022, Oxford University Press (OUP)

    Professor Gerald Raverot

  17. Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas

    Article • Endocrine Reviews, October 2022, Endocrine Society

    Professor Gerald Raverot

  18. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

    Article • European Journal of Endocrinology, September 2022, Oxford University Press (OUP)

    Professor Gerald Raverot

  19. The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal?

    Article • Cancers, August 2022, MDPI AG

    Professor Gerald Raverot

  20. Aggressive corticotroph tumors and carcinomas

    Article • Journal of Neuroendocrinology, August 2022, Wiley

    Professor Gerald Raverot

  21. Prolactin immunoassay: does the high-dose hook effect still exist?

    Article • Pituitary, July 2022, Springer Science + Business Media

    Professor Gerald Raverot

  22. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review

    Article • Endocrine Related Cancer, July 2022, Bioscientifica

    Professor Gerald Raverot

  23. Clinical Biology of the Pituitary Adenoma

    Article • Endocrine Reviews, April 2022, Endocrine Society

    Professor Gudmundur Johannsson, Professor Gerald Raverot

  24. First case of chronic post-traumatic anterior pituitary dysfunction in a professional rugby player: A case report

    Article • Annales d Endocrinologie, April 2022, Elsevier

    Professor Gerald Raverot

  25. Aggressive Pituitary Adenomas

    Article • January 2022, Elsevier

    Professor Gerald Raverot

  26. Aggressive pituitary tumours and pituitary carcinomas

    Article • Nature Reviews Endocrinology, September 2021, Springer Science + Business Media

    Professor Gerald Raverot

  27. Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)

    Article • Cancers, April 2021, MDPI AG

    Professor Gerald Raverot

  28. Letter to the Editor From Helene Lasolle and Gérald Raverot: “USP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors”

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2021, Endocrine Society

    Professor Gerald Raverot

  29. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up

    Article • Journal of Clinical Medicine, October 2020, MDPI AG

    Professor Gerald Raverot

  30. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature

    Article • Journal of Personalized Medicine, August 2020, MDPI AG

    Professor Gerald Raverot

  31. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2020, Endocrine Society

    Professor Gerald Raverot

  32. Treatment Options for Gonadotroph Tumors: Current State and Perspectives

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2020, Endocrine Society

    Professor Gerald Raverot

  33. Urinary free cortisol: An automated immunoassay without extraction for diagnosis of Cushing’s syndrome and follow‐up of patients treated by anticortisolic drugs

    Article • Clinical Endocrinology, May 2020, Wiley

    Professor Gerald Raverot

  34. Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy

    Article • Cancers, April 2020, MDPI AG

    Professor Gerald Raverot

  35. How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020

    Article • Cancers, February 2020, MDPI AG

    Professor Gerald Raverot

  36. The Microenvironment of Pituitary Tumors—Biological and Therapeutic Implications

    Article • Cancers, October 2019, MDPI AG

    Professor Gerald Raverot

  37. Aggressive prolactinomas: how to manage?

    Article • Pituitary, October 2019, Springer Science + Business Media

    Professor Gerald Raverot

  38. Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas with Hypothalamic Involvement?

    Article • World Neurosurgery, September 2019, Elsevier

    Professor Gerald Raverot

  39. Emerging and Novel Treatments for Pituitary Tumors

    Article • Journal of Clinical Medicine, July 2019, MDPI AG

    Professor Gerald Raverot

  40. Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification

    Article • Pituitary, July 2019, Springer Science + Business Media

    Professor Gerald Raverot

  41. Cabergoline in severe ectopic or occult Cushing’s syndrome

    Article • European Journal of Endocrinology, July 2019, Oxford University Press (OUP)

    Professor Gerald Raverot

  42. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment

    Article • Minerva Endocrinologica, May 2019, Edizioni Minerva Medica

    Professor Gerald Raverot

  43. Pasireotide: A potential therapeutic alternative for resistant prolactinoma

    Article • Annales d Endocrinologie, April 2019, Elsevier

    Professor Gerald Raverot

  44. Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency

    Article • Polish Archives of Internal Medicine, January 2019, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

    Professor Gerald Raverot

  45. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours

    Article • Neuroendocrinology, January 2019, Karger Publishers

    Professor Gerald Raverot

  46. Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability

    Article • Frontiers in Endocrinology, November 2018, Frontiers

    Professor Gerald Raverot

  47. Correction to: Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study

    Article • Endocrine, October 2018, Springer Science + Business Media

    Professor Gerald Raverot

  48. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study

    Article • Endocrine, September 2018, Springer Science + Business Media

    Professor Gerald Raverot

  49. Unusual neurologic presentation of aseptic abscesses syndrome

    Article • Neurology Neuroimmunology & Neuroinflammation, June 2018, Wolters Kluwer Health

    Professor Gerald Raverot

  50. Aggressive pituitary tumours and carcinomas: two sides of the same coin?

    Article • European Journal of Endocrinology, March 2018, Bioscientifica

    Professor Gerald Raverot

  51. Centralization errors in comparative genomic hybridization array analysis of pituitary tumor samples

    Article • Genes Chromosomes and Cancer, March 2018, Wiley

    Professor Gerald Raverot

  52. Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET)

    Article • Cell Cycle, March 2018, Taylor & Francis

    Professor Gerald Raverot

  53. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a Compassionate Use Programme in France

    Article • European Journal of Endocrinology, February 2018, Bioscientifica

    Professor Gerald Raverot

  54. MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis

    Article • European Journal of Endocrinology, February 2018, Bioscientifica

    Professor Gerald Raverot

  55. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

    Article • European Journal of Endocrinology, January 2018, Bioscientifica

    Professor Gerald Raverot, Professor Gudmundur Johannsson

  56. Prognostic factors of regrowth in nonfunctioning pituitary tumors

    Article • Pituitary, December 2017, Springer Science + Business Media

    Professor Gerald Raverot

  57. Triple-A syndrome: a wide spectrum of adrenal dysfunction

    Article • European Journal of Endocrinology, December 2017, Bioscientifica

    Mrs Florence Roucher, Professor Gerald Raverot

  58. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

    Article • European Journal of Endocrinology, October 2017, Bioscientifica

    Professor Gerald Raverot

  59. Reconsidering olfactory bulb magnetic resonance patterns in Kallmann syndrome

    Article • Annales d Endocrinologie, October 2017, Elsevier

    Professor Gerald Raverot

  60. Risks and Benefits of Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas in Patients of the Ninth Decade

    Article • World Neurosurgery, October 2017, Elsevier

    Professor Gerald Raverot

  61. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

    Article • Pituitary, September 2017, Springer Science + Business Media

    Professor Gerald Raverot, Professor Gudmundur Johannsson

  62. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2017, Endocrine Society

    Professor Gerald Raverot

  63. Transdifferentiation of Neuroendocrine Cells

    Article • The American Journal of Surgical Pathology, June 2017, Wolters Kluwer Health

    Adrian Daly, Professor Gerald Raverot

  64. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

    Article • European Journal of Endocrinology, April 2017, Bioscientifica

    Professor Gerald Raverot

  65. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal

    Article • Endocrine Related Cancer, March 2017, Bioscientifica

    Sylvia Asa, Professor Gerald Raverot

  66. MicroRNAs in pituitary tumors

    Article • Molecular and Cellular Endocrinology, January 2017, Elsevier

    Professor Gerald Raverot

  67. An old retrocardiac mass fortuitously reclassified as paraganglioma

    Article • Annales d Endocrinologie, December 2016, Elsevier

    Professor Gerald Raverot

  68. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature

    Article • European Journal of Endocrinology, November 2016, Bioscientifica

    Professor Gerald Raverot

  69. Dramatic change in skin color after bilateral adrenalectomy in Cushing's disease

    Article • Annales d Endocrinologie, October 2016, Elsevier

    Professor Gerald Raverot

  70. Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys® Cortisol II assay

    Article • Annales d Endocrinologie, October 2016, Elsevier

    Professor Gerald Raverot

  71. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

    Article • Endocrine Related Cancer, September 2016, Bioscientifica

    Dr Irena Ilovayskaya, Adrian Daly, Professor Gerald Raverot

  72. Therapeutic innovations in endocrine diseases – part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas

    Article • La Presse Médicale, June 2016, Elsevier

    Professor Gerald Raverot

  73. The silent somatotroph tumours

    Article • Endocrine Abstracts, May 2016, Bioscientifica

    Professor Gerald Raverot

  74. Pituitary siderosis: the dark side of the pituitary

    Article • The Lancet Diabetes & Endocrinology, April 2016, Elsevier

    Professor Gerald Raverot

  75. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors

    Article • Molecular Cancer Therapeutics, March 2016, American Association for Cancer Research (AACR)

    Professor Gerald Raverot

  76. Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome

    Article • Annales d Endocrinologie, February 2016, Elsevier

    Professor Gerald Raverot

  77. Dilated Cardiomyopathy Revealing Cushing Disease

    Article • Medicine, November 2015, Wolters Kluwer Health

    Professor Gerald Raverot

  78. Biological and radiological exploration and management of non-functioning pituitary adenoma

    Article • Annales d Endocrinologie, July 2015, Elsevier

    Professor Gerald Raverot

  79. HMGA1-pseudogene expression is induced in human pituitary tumors

    Article • Cell Cycle, April 2015, Taylor & Francis

    Professor Gerald Raverot

  80. Pituitary Involvement in Granulomatosis With Polyangiitis

    Article • Medicine, April 2015, Wolters Kluwer Health

    Professor Gerald Raverot

  81. Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth

    Article • March 2015, Bioscientifica

    Professor Gerald Raverot, Etienne Delgrange

  82. Macroprolactinaemia: a biological diagnostic strategy from the study of 222 patients

    Article • March 2015, Bioscientifica

    Professor Gerald Raverot

  83. A Prognostic Clinicopathologic Classification of Pituitary Endocrine Tumors

    Article • Endocrinology and Metabolism Clinics of North America, March 2015, Elsevier

    Professor Gerald Raverot

  84. Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2015, Endocrine Society

    Professor Gerald Raverot

  85. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences

    Article • January 2015, Bioscientifica

    Professor Gerald Raverot, Adrian Daly

  86. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

    Article • The Lancet Diabetes & Endocrinology, November 2014, Elsevier

    Professor Gerald Raverot

  87. miR-23b and miR-130b expression is downregulated in pituitary adenomas

    Article • Molecular and Cellular Endocrinology, June 2014, Elsevier

    Professor Gerald Raverot

  88. Ketoconazole in Cushing's Disease: Is It Worth a Try?

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2014, Endocrine Society

    Professor Gerald Raverot

  89. MANAGEMENT OF ENDOCRINE DISEASE: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies

    Article • January 2014, Bioscientifica

    Professor Gerald Raverot

  90. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies

    Article • Human Pathology, January 2014, Elsevier

    Professor Gerald Raverot

  91. Silent GH pituitary tumor: Diagnostic and therapeutic challenges

    Article • Annales d Endocrinologie, December 2013, Elsevier

    Professor Gerald Raverot

  92. Non-functioning pituitary macro-incidentalomas benefit from early surgery before becoming symptomatic

    Article • Clinical Neurology and Neurosurgery, December 2013, Elsevier

    Professor Gerald Raverot, Dr Moncef Berhouma

  93. Massive prolactinoma in women: a study of 15 cases

    Article • October 2013, Bioscientifica

    Etienne Delgrange, Professor Ulla Feldt-Rasmussen, Professor Gerald Raverot

  94. BKM120, a pure PI3K inhibitor: a promising treatment for aggressive pituitary tumors or pituitary carcinomas

    Article • Endocrine Abstracts, April 2013, Bioscientifica

    Professor Gerald Raverot

  95. Expression of somatostatin receptors, SSTR2Aand SSTR5, in 108 pituitary adenomas, using immunohistochemical detection with specific MABs

    Article • Endocrine Abstracts, April 2013, Bioscientifica

    Professor Gerald Raverot

  96. Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide

    Article • Cancer Investigation, March 2013, Taylor & Francis

    Professor Gerald Raverot

  97. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

    Article • Acta Neuropathologica, February 2013, Springer Science + Business Media

    Professor Gerald Raverot

  98. 18F-FDG PET/CT Findings in a Patient With Isolated Intracranial Rosai-Dorfman Disease

    Article • Clinical Nuclear Medicine, January 2013, Wolters Kluwer Health

    Professor Gerald Raverot

  99. Acromegaly induced by ectopic secretion of GHRH: A review 30 years after GHRH discovery

    Article • Annales d Endocrinologie, December 2012, Elsevier

    Professor Gerald Raverot

  100. Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2012, Endocrine Society

    Professor Gerald Raverot

  101. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients

    Article • QJM, June 2012, Oxford University Press (OUP)

    Professor Gerald Raverot

  102. Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2012, Endocrine Society

    Professor Gerald Raverot

  103. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

    Article • Clinical Endocrinology, April 2012, Wiley

    Professor Gerald Raverot

  104. Insuffisances antéhypophysaires post-traumatismes crâniens : quel retentissement ? quel bilan ?

    Article • Revue Neurologique, April 2012, Elsevier

    Professor Gerald Raverot

  105. New targeted therapies in pituitary carcinoma resistant to temozolomide

    Article • Pituitary, August 2011, Springer Science + Business Media

    Professor Gerald Raverot

  106. Ectopic ACTH Syndrome in Children and Adolescents

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2011, Endocrine Society

    Professor Gerald Raverot

  107. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal

    Article • Neurosurgical FOCUS, April 2011, Journal of Neurosurgery Publishing Group (JNSPG)

    Professor Gerald Raverot, Pr Messerer M M Mahmoud

  108. Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors

    Article • Brain Pathology, February 2011, Wiley

    Professor Gerald Raverot

  109. Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2010, Endocrine Society

    Professor Gerald Raverot, Adrian Daly

  110. Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2010, Endocrine Society

    Professor Gerald Raverot

  111. Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach

    Article • Molecular and Cellular Endocrinology, September 2010, Elsevier

    Professor Gerald Raverot

  112. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease

    Article • April 2010

    Professor Gerald Raverot

  113. Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2010, Endocrine Society

    Professor Gerald Raverot

  114. Cabergoline therapy of paraneoplastic cushing syndrome in children

    Article • Pediatric Blood & Cancer, March 2010, Wiley

    Professor Gerald Raverot

  115. Sex hormone-binding globulin gene expression in the liver: Drugs and the metabolic syndrome

    Article • Molecular and Cellular Endocrinology, March 2010, Elsevier

    Professor Gerald Raverot

  116. Carcinome hypophysaire

    Article • January 2010, Springer Science + Business Media

    Professor Gerald Raverot

  117. Résultats comparés de la chirurgie endoscopique et de la microchirurgie dans une série consécutive de macroadénomes hypophysaires non fonctionnels

    Article • Neurochirurgie, December 2009, Elsevier

    Professor Gerald Raverot

  118. Reply

    Article • American Journal of Ophthalmology, June 2009, Elsevier

    Professor Gerald Raverot

  119. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma

    Article • Clinical Endocrinology, March 2009, Wiley

    Professor Gerald Raverot

  120. Predicting Visual Outcome After Treatment of Pituitary Adenomas With Optical Coherence Tomography

    Article • American Journal of Ophthalmology, January 2009, Elsevier

    Professor Gerald Raverot

  121. Familial pituitary adenomas with a heterogeneous functional pattern: Clinical and genetic features

    Article • Journal of Endocrinological Investigation, October 2007, Springer Science + Business Media

    Professor Gerald Raverot

  122. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors

    Article • September 2007, Bioscientifica

    Professor Gerald Raverot

  123. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2007, Endocrine Society

    Professor Gerald Raverot, Adrian Daly

  124. P1-038 - Efficacité et tolérance à long terme du traitement médical des macroprolactinomes

    Article • Annales d Endocrinologie, October 2006, Elsevier

    Professor Gerald Raverot

  125. Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2006, Endocrine Society

    Professor Gerald Raverot

  126. Sox3 expression in undifferentiated spermatogonia is required for the progression of spermatogenesis

    Article • Developmental Biology, July 2005, Elsevier

    Professor Gerald Raverot

  127. Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development

    Article • Development, May 2005, The Company of Biologists

    Professor Gerald Raverot

  128. X-Linked Sex-Determining Region Y Box 3 (SOX3) Gene Mutations Are Uncommon in Men with Idiopathic Oligoazoospermic Infertility

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2004, Endocrine Society

    Professor Gerald Raverot

  129. Influence ofSHBGGene Pentanucleotide TAAAA Repeat and D327N Polymorphism on Serum Sex Hormone-Binding Globulin Concentration in Hirsute Women

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2004, Endocrine Society

    Professor Gerald Raverot

  130. Sox3 Is Required for Gonadal Function, but Not Sex Determination, in Males and Females

    Article • Molecular and Cellular Biology, November 2003, ASM Journals

    Professor Gerald Raverot

  131. Syndrome de Klinefelter et microinjections intraovocytaires de spermatozoïdes (revue de la littérature)

    Article • Andrologie, June 2003, Springer Science + Business Media

    Professor Gerald Raverot